Program Indication Discovery IND Approval Phase I Phase II

AND017 (HIF-PHI)
Anemia

Phase II FDA Approval in Jan 2021


AND019(SERD)
Breast Cancer

Phase I IND Enabling


ADC
Cancers

Pre-Clinical


AND021
Renal Cell Carcinoma

Pre- Clinical